SCHEMBL5202072

SCHEMBL5202072

Fc1cccc(F)c1Cn1c(-c2c(F)cccc2F)nc2c(CCl)cccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
GAA P10253 1/20 0.39
KCNK13 Q9HB14 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CDK2 P24941 1/20 0.33
THRB P10828 1/20 0.33
GRM2 Q14416 1/20 0.33
PDE2A O00408 2/20 0.32
PDE10A Q9Y233 2/20 0.32
JAK2 O60674 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204113 0.87 TLR8 (0.43) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5200966 0.87 MAPT (0.40) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5202583 0.87 TP53 (0.39) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5203923 0.85 MAPT (0.39) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5204066 0.84 MAPT (0.48) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5203916 0.84 TP53 (0.36) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL14540341 0.83 TLR8 (0.40) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5203544 0.82 TLR8 (0.41) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5205430 0.82 ALDH1A1 (0.37) MAPTTP53GAAKCNK13ALDH1A1
SCHEMBL5201969 0.81 GRM2 (0.42) MAPTTP53GAAKCNK13ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1210336-B1 SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE US HEALTH (US) 2007-04-25 EP disclosed
US-6894068-B2 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-05-17 US disclosed
US-20030191160-A1 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase MICHEJDA CHRISTOPHER J (US) 2003-10-09 US disclosed
US-6369235-B1 INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2002-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191160-A1 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase SAMHD1, DUT, TYMP MAPT 2190/4885TP53 3145/4885GAA 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.